drugset / Trial / NCT01712763

Degarelix in the Treatment of Endometriosis Recurrence

NCT01712763

RandomizedParallel-groupSingle-blindTreatment

Summary

The long acting GnRH antagonist degarelix will be tested for the treatment of women with endometriosis recurrence compared with classical GnRH analog treatment. Pain symptom disappearance and disease free time during follow-up will be the outcomes for establishing which medical treatment is the best in endometriosis recurrence treatment.

Timeline

Start
2012-11
Primary completion
2016-03
Completion
2016-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Degarelix Other / unclassified 120 mg
Comparator Leuprolide Other / unclassified 11.25 mg/ml

Indications